Master-level internship (Master 2) in Innovative Therapeutics and Precision Oncology

Host Laboratory 

Laboratory : The Anticipe Unit conducts both fundamental and applied research to offer cancer prevention or treatment strategies best adapted to individuals and their environment. In daily interaction with clinicians from the University Hospital and François Baclesse Comprehensive Cancer Center, the unit comprises about a hundred people and two main research axes: "Cancers and Prevention" and "Precision Medicine for Ovarian Cancer." This project is part of the "Precision Medicine for Ovarian Cancer" axis and is a new theme within the unit, involving the THERANOVCA Excellence Chair in innovative theranostic approaches for ovarian cancers and the international partner laboratory RECITAL with the University of Sherbrooke (QC, Canada). 

Supervision : Dr. Élie Besserer-Offroy, Assoc. Prof. et Dr. Cécile Pétigny, Assoc. Researcher. 

Expertise : Pharmacology of G protein-coupled receptors (GPCRs), Nuclear Medicine and Theranostics, Radioligand Development, Ovarian Cancer, Precision Medicine. 

Internship Context 

Locally aggressive cancers, especially ovarian cancers, represent major therapeutic challenges requiring the development of new diagnostic and therapeutic strategies. In this context, innovative preclinical models are essential for evaluating the efficacy of new therapeutic molecules. 

This internship is part of a research project aimed at developing new theranostic molecules, combining molecular imaging and radioligand therapies (targeted radionuclide therapy). The work carried out during this internship will provide the methodological foundations for a future doctoral project.